Contact Us |
The Immunobiology Working Committee (IBWC) is the largest committee of the CIBMTR by study volume and addresses scientific questions about the association between genetic factors and successful transplantation outcomes. The IBWC welcomes studies that assess genes and gene products of the major histocompatibility complex, natural killer cell repertoire, cytokine / proinflammatory cytokine and immune-response determinants, minor histocompatibility loci, and other genetic factors. The committee’s studies also include comparisons of clinical outcomes from different donor types, such as mismatched related versus unrelated donors, and exploration of novel biostatistical and analytic approaches to investigate the impact of various HLA mismatches.
The NMDP/Be The Match Research Sample Repository provides a unique resource for investigators conducting retrospective analyses of immune-response determinants and transplant outcomes. Currently, samples are available from more than 34,000 unrelated donor / cord blood-recipient pairs and 3,300 related donor pairs for whom complete clinical data have been collected and validated. Last year, the Repository distributed more than 8,700 aliquots to investigators. Current inventory may be viewed and requests for samples may be submitted using the instructions on the Sample Types and Inventory Summary webpage.
For studies that examine the clinical role of the immune system in transplantation and do not require complete high-resolution HLA typing data and / or samples, the CIBMTR can provide clinical data on more than 43,500 HLA-identical sibling, 7,400 other-related, and 36,000 unrelated donor transplants. The IBWC currently lists 42 studies in progress, some in collaboration with other research organizations, such as the International Histocompatibility Working Group, EBMT, and Eurocord. Publications from the IBWC may be accessed on the IBWC Studies webpage.
PublicationsThere are 62 BMT CTN published articles, including 18 primary analyses. The following primary results manuscripts were recently published.
About the BMT CTNThe CIBMTR shares administration of the BMT CTN Data and Coordinating Center with NMDP/Be The Match and The Emmes Corporation. Together, these three organizations support all BMT CTN activities. The BMT CTN Steering Committee is currently under the leadership of Chair Steve Devine, MD (Ohio State University Medical University); Chair-Elect Rick Jones, MD (Johns Hopkins University); and Past-Chair Fred Appelbaum, MD (Fred Hutchinson Cancer Research Center).To get up-to-date information about BMT CTN studies, meetings and news:
Like us on Facebook: facebook.com/bmtctnFollow us on Twitter: @BMTCTN
Return to Top
Cellular Therapy Data CollectionBy Tiffany Hunt, MS, CCRP, and Emilie Love, CSPO
The world of cellular therapies is expanding. The science of infusions changes rapidly, requiring continuous review of CIBMTR forms. To better capture new data available on cellular therapies, and in conjunction with the Form Revision process, the CIBMTR expanded its cellular therapy data collection forms. Over the past year, a team of experts worked to develop new cellular therapy forms, which will be available in the Summer Release. These forms include:
*Genetically modified products reported to the CIBMTR will have a modified forms due schedule. Per FDA requirements, follow-up on genetically modified products is required for 15 years.
Tasked with identifying patient-centered questions that lend themselves to comparative effectiveness clinical studies, the working groups will present the results of their deliberations for feedback at the second symposium. Tentative plans are to hold the second symposium in the evening on Friday, December 2, prior to the start of the annual ASH meeting in San Diego.
We also developed two webinars that will be held in October and November. The first, Transplant Outcomes that Matter Most to Patients, is scheduled for October 18 and will target patients / caregivers and other stakeholders to engage them in the project. The second, Patient Reported Outcomes Research in Hematopoietic Cell Transplantation, is scheduled for November 16 and will target investigators who are interested in patient-centered outcomes research. We will highlight the research of Heather Jim, PhD; Bill Wood, MD; and Bronwen Shaw, MBChB, PhD. Mark your calendars, spread the word to patients / caregivers / families and colleagues, and plan to join us for the webinars and December symposium.Impact of BMT CTN 0201 on Clinical PracticeIn June, in collaboration with Nandita Khera, MD, we launched a survey of clinicians who advise patients on stem cell sources for allogeneic transplant based on the BMT CTN 0201 prospective, randomized trial that compared unrelated donor peripheral blood and bone marrow as stem cell sources. While overall survival was similar, peripheral blood stem cells were associated with more chronic GVHD, whereas bone marrow stem cells were associated with more graft failure. Since publication of results in October 2012, there has been no impact on the proportion of peripheral blood versus bone marrow stem cell transplants performed. With survey data, we hope to better understand the drivers and barriers to translation of clinical study results into clinical practice. Palliative CareDelivery of effective palliative care to patients with hematologic diseases and those undergoing transplant is an unmet need. The Health Services Research Program continues to work closely with the ASBMT Palliative Care Task Force to conduct a survey of clinicians regarding perceptions and availability / utilization of palliative care options for their patients. Be sure to watch your inbox in the coming month for the survey – your input is invaluable in this critical area.Health Care Costs and UtilizationCosts and utilization of allogeneic HCT compared with chemotherapy alone as initial therapy for older patients with AML is a major focus of our research portfolio. We recently published a “lessons learned” manuscript for those working with administrative claims data, and the analysis of costs and utilization is nearing completion. A second project merged the Centers for Medicare and Medicaid Services database with the CIBMTR Research Database to permit a similar analysis that includes outcomes and a cost-effectiveness component.Outcomes of transplant for AML are better earlier than later in the disease course; unfortunately, many patients undergo transplant in second remission and beyond. To identify barriers to early referrals and strategies for intervention, we conducted a survey of practicing community hematologists / oncologists (NCCN / Pfizer funded). We are now developing three AML educational webinars to address identified knowledge gaps that impact timing of referral, including cytogenetic / molecular markers for prognostication (September 29), management of AML in first clinical remission (October 20), and therapeutic options for older patients (November 17). Help us advertise the webinars to your center’s referring physicians and clinics.Other Studies in Our Research Portfolio
Recent Peer-Reviewed Publications
Contact Ellen Denzen, MS, Senior Manager of Health Services Research with questions.
SCTOD Expands Communication and Hosts Center Outcomes ForumBy Carol Doleysh
Summaries are created through a collaborative process involving CIBMTR Consumer Advocacy Committee members; CIBMTR and NMDP/Be The Match Medical Writers, Communications Specialists, and Patient Education Specialists; and CIBMTR Scientific Directors. Developing these summaries is one of the main initiatives of the Consumer Advocacy Committee.
The Consumer Advocacy Committee was created in 2005 as a subcommittee of the Advisory Committee to communicate CIBMTR research results and data to the non-medical community and to provide patient and donor perspectives during the development of the CIBMTR research agenda. Many members have personal experience as a donor, recipient, or family member.
CIBMTR on Facebook and TwitterLike us on Facebook and follow us on Twitter to stay up-to-date with important news and events. We promote our publications, share important content from other organizations, and advertise our key meetings and events. Join us today!
CIBMTR Advisory CommitteeThe Advisory Committee, made up of members from across the globe, maintains careful oversight of the CIBMTR research agenda. Visit the Advisory Committee webpage to view the list of committee members. We sincerely thank all of our committee members for their time and efforts, particularly Jim Omel, MD, who completed his term June 30. We also welcome Jeff Haertling who joins us as of July 1.